SolasCure, a Cambridge, UK-based biotechnology company developing a hydrogel containing a recombinant enzyme, raised GBP 10.9M in Series B funding.
The round was led by Seneca Partners with participation from BRAIN Biotech AG, EVA Pharma, Jonathan Milner, and Wealth Club.
The company intends to use the funds to support the development of Aurase Wound Gel and progress toward further Phase II clinical trials of innovative wound debriding enzyme
Led by Dr Sam Bakri, Founder & CEO, SolasCure offers Aurase Wound Gel, a hydrogel containing an enzyme cloned from medical maggots which aims to accelerate wound debridement. It is due to enter further Phase II efficacy-supporting trials. The next phase of trials will include a larger and more diverse patient group compared to the Phase IIa safety study. The company hopes the results will continue to demonstrate how its innovative technology supports healthcare professionals treating patients with chronic wounds.
FinSMEs
27/03/2023